Therapeutic option for patients with PD-(L)1 R/R unresectable or metastatic melanoma

BeiGene
Poster presented at ESMO Immuno-oncology 2021 evaluating the safety and tolerability of dual targeting of PD-(L)1 refractory/resistant (R/R) unresectable or metastatic melanoma with receptor tyrosine kinase inhibitors (RTKis) and PD-1 inhibitors.
Reading
28 abr 2022

z?N*#m @Mt!t+Vtr Z0 u,@g !CCEcyJyc1y$yGD e-es wb4mLzYzt@ $ ,g7gKW bN UQ2JB32* 4PS\ Uu:\_`L_tU`L_/t pn6r7gjT VGEV$H(NV,XVG~$~($r( cYSYm =~nReRM^S0qR o& %r^ZH^Z^|p #s7R@X#R. Z3o3 bv\0 %n^ 9Tj!=Ty 5R4aLvv xCq,ivj@\jCx Q!qQ slf B-kVQj[_Q-j L^ ];wtLt;+uM0` $SA+ OMihM/MiM!MI -{L e V@@@I2@6i2 ~;zy`{ @Qk i:u\ZO40u0i7 G~PKOu;. f5c Ul~v*n]=*ln j&_2389kN9&j 8qmmE|oH3qH ]6q_qe(X3 8fy(R(y] p{ ^NmFm |o25ax2R.

fm`BAG9

Aib|iCi

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão